IRD Opus Genetics Inc: Indikator likuiditas cepet

Opus Genetics Inc (IRD) relies on patent protection for its retinal genetic treatment developments, ensuring high profitability through exclusive statuses in the US. Despite the risks of a scientific race, the company successfully resists expansion from high-tech implant manufacturers. The current metric is 11.82. This price chart complements the data on the biopharmaceutical startup creating innovative AAV vectors.

For Opus Genetics Inc (IRD), which operates in the high-margin segment of hereditary retinal pathology therapy, the quick ratio demonstrates the ability to service debts without liquidating inventory. This metric compares current liabilities exclusively against cash and accounts receivable, excluding low-liquidity inventories, which allows for an objective assessment of the business's financial autonomy and viability within a niche client market.